Form 4: Amgen Director Greg C. Garland Receives Stock Grant
Director Equity Compensation Disclosure
Amgen Inc. director Greg C. Garland acquired 665 shares of common stock through the immediate vesting of restricted stock units.
Summary
- Director Greg C. Garland was granted 665 restricted stock units (RSUs) on May 19, 2026.
- The RSUs vested immediately upon grant under the Amgen Inc. 2009 Director Incentive Program.
- Following this transaction, the director's total beneficial ownership in Amgen common stock increased to 13,848 shares.
- The shares were acquired at a price of $0, representing a standard equity compensation grant for board members.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a neutral event, as it represents standard director compensation and does not signal a change in company strategy or financial health.
Positives
- Alignment of director interests with shareholders through increased equity ownership.
- Standardized compensation practice under the established 2009 Equity Incentive Plan.
Negatives
- None identified; this is a routine disclosure of director compensation.
Risks
- None identified; this is a routine administrative filing regarding director equity.
Future Outlook
The filing does not provide forward-looking financial guidance, as it is a disclosure of director equity compensation.
Industry Context
StockSavvy.ai notes that this filing is a routine regulatory disclosure common among large-cap pharmaceutical companies, reflecting standard board compensation practices rather than a strategic shift or market-moving event.
Comparison to Industry Standards
- The grant of RSUs to non-employee directors is a standard practice among S&P 500 companies to ensure board alignment with long-term shareholder value.
- The transaction size is consistent with typical director compensation packages for a company of Amgen's market capitalization.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Grant | Grant of 665 RSUs to Director Greg C. Garland under the 2009 Director Incentive Program. | 05/19/2026 | Minimal; routine compensation adjustment. |
Stakeholder Impact
- Shareholders: Neutral impact as this is a standard component of director compensation.
Next Steps
- No future actions or milestones were disclosed in this filing.
Key Dates
| Date | Description |
|---|---|
| 05/19/2026 | Date of the RSU grant and immediate vesting transaction. |
Keywords
Amgen, AMGN, Director Compensation, Insider Transaction, Equity Incentive Plan, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.